Core Viewpoint - Teladoc Health has experienced a significant decline in stock value, down nearly 92% over the past six years, and is unlikely to recover soon, making it a risky investment choice [1][2]. Group 1: Competition - The pandemic success of Teladoc attracted substantial competition, including from major corporations like Amazon, which has a strong brand and a large customer base [4][5]. - Other companies, including insurance firms, are also entering the telemedicine space, posing further threats to Teladoc's market position [5]. Group 2: Growth Drivers - Teladoc's virtual mental health service, BetterHelp, which was a key growth driver, has been struggling and is now a burden on revenue growth, losing paying members [6]. - Despite attempts to turn around its fortunes through international expansion, the company may face similar challenges abroad as it has in the U.S. [8][9]. Group 3: Financial Performance - Teladoc has not yet achieved profitability, and its sales growth has been slow or nonexistent, leading to a loss of market share [7][8]. - The company has a market capitalization of $1.3 billion, with a gross margin of 55.61%, but consistent net losses raise concerns about its financial health [7].